The National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) has awarded Rivanna a $2.21 million small business innovation research direct to phase II grant.
The funding supports the development of an ultrasound guidance system for pediatric lumbar punctures on Rivanna's Accuro 3S platform. The platform will be adapted to support a broad spectrum of pediatric body sizes, from infants with delicate anatomy to adolescents with high body mass index (BMI), according to the firm.
Rivanna aims to address an unmet need for dedicated pediatric lumbar puncture features as part of an advanced, compact, AI-enabled bedside ultrasound system.
Lumbar punctures are used to confirm the diagnosis of acute lymphoblastic leukemia, as well as deliver intrathecal chemotherapy, the company explained, noting that traditional lumbar puncture procedures are challenging in very young children and those with a high BMI and can lead to traumatic lumbar punctures.
"By minimizing failed attempts and [traumatic lumbar punctures], Accuro 3S has the potential to improve treatment outcomes and support increased survival rates for children with [acute lymphoblastic leukemia], while improving patient and provider satisfaction," the company said.
